EUVIMEDEUVIMED entdecken
Crossref

Cross Fire: BTK Inhibitors Alone or in Combination are the Best Frontline Therapy for CLL

Theo Sottero, Farrukh T Awan

Hematology/Oncology and Stem Cell Therapy · 2023

DOI: 10.56875/2589-0646.1040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2023. Verfasst von Theo Sottero und 1 weiteren Autor:innen. Beteiligte Einrichtung: Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BTK (Bruton's tyrosine kinase) inhibitors are highly effective front-line therapy for CLL (chronic lymphocytic leukemia) due to high response rates and prolonged progression-free survival, even in patients with high-risk disease features. They are also generally well tolerated, with the newer BTK inhibitors demonstrating better tolerability than ibrutinib while maintaining efficacy. Adverse effects such as bleeding or infections are usually manageable with supportive care or dose adjustments. Orally administered BTK inhibitors do not require intensive or inpatient monitoring and improve quality-of-life outcomes. Moreover, the established activity of venetoclax in the setting of BTK inhibitor failure is also reassuring as a salvage option. Nevertheless, the advantage of venetoclax as a time-limited treatment option is substantial, despite its inferior progression-free survival, since these patients can get another challenge with a reasonable chance of success. BTK inhibitors after venetoclax may be effective, but long-term data is limited. Given these reasons, BTK inhibitors remain the preferred treatment option as initial therapy for patients with CLL, especially those with del17p or TP53 mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellHumansAgammaglobulinaemia Tyrosine KinaseBridged Bicyclo Compounds, HeterocyclicSulfonamidesProtein Kinase Inhibitors

Substanzen

venetoclaxAgammaglobulinaemia Tyrosine KinaseBridged Bicyclo Compounds, HeterocyclicSulfonamidesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Zitieren

APA

Sottero, T., & Awan, F. T. (2023). Cross Fire: BTK Inhibitors Alone or in Combination are the Best Frontline Therapy for CLL. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.56875/2589-0646.1040

Vancouver

Sottero T, Awan FT. Cross Fire: BTK Inhibitors Alone or in Combination are the Best Frontline Therapy for CLL. Hematology/Oncology and Stem Cell Therapy. 2023. doi:10.56875/2589-0646.1040

BibTeX
@article{Sottero2023,
  author = {Sottero, Theo and Awan, Farrukh T},
  title = {Cross Fire: BTK Inhibitors Alone or in Combination are the Best Frontline Therapy for CLL},
  journal = {Hematology/Oncology and Stem Cell Therapy},
  year = {2023},
  doi = {10.56875/2589-0646.1040}
}
Kostenlos starten →